• Dr. Joshua Allen, VP of Research and Development at Oncoceutics, will present a talk titled “Activity of the Selective DRD2 Antagonist
    ONC201 in Recurrent Glioblastoma” at the Brain Tumor Biotech Summit 2017 at Lenox Hill Hospital in New York on June 2nd.

    The full agenda can be found here.

Photostream